FDA

research

BioCryst Upgrade Almost Looks Misunderstood

The most recent analyst call by Merrill Lynch for BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) may be very misunderstood for what it is. The brokerage firm upgraded BioCryst to Neutral and ...
Read Full Story »
knees

Is Ampio at Risk of Imploding?

Companies in the biotech and pharmaceuticals field are generally riskier than other companies because a single failed study could make or break the company, similar to what happened with Ampio ...
Read Full Story »
cannabis

Is Legalized Marijuana Coming to 3 More States?

The efforts and controversy behind medical marijuana and legalized marijuana for recreational use have been at a crossroads for some time. Several states have legalized marijuana for recreational and medical ...
Read Full Story »
thumbs up

Analysts Massively Increasing Dyax Price Targets

The next hot biotech stock could very well be Dyax Corp. (NASDAQ: DYAX). With biotech such a hot sector of late, investors are likely to pay close attention to this ...
Read Full Story »
health care

Why Dyax Will Dominate Biotech News on Wednesday

Dyax Corp. (NASDAQ: DYAX) is almost certain to dominate the biotech news flow on Wednesday. The company announced positive data on Tuesday evening from the Phase 1b clinical study of the ...
Read Full Story »
fda_logo

Can AcelRx Overcome Yet Another FDA Roadblock?

AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX) announced an update on the timing and potential content of its resubmission of the New Drug Application (NDA) for Zalviso. Unfortunately the update was not ...
Read Full Story »
biotech

Oncolytics Newest Orphan Drug Designation

Oncolytics Biotech Inc. (NASDAQ: ONCY) announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation for Reolysin. Reolysin is the company’s lead product candidate that is designated ...
Read Full Story »
Pills

Why 1 Analyst Sees Over 50% Upside in Sarepta

Sarepta Therapeutics Inc. (NASDAQ: SRPT) received a favorable rating from Merrill Lynch, and as a result the stock was climbing in Tuesday’s trading session. The firm raised its rating to ...
Read Full Story »
Pills

Is a Generic Nexium Purple Pill for You?

When it comes to drugs being overly advertised, the Purple Pill, or Nexium, has been advertised over and over for years now. Now the question to ask is if a ...
Read Full Story »
cannabis

GW Cannabinoid Drug Fails Cancer Pain Trial

GW Pharmaceuticals PLC (NASDAQ: GWPH) and Otsuka Pharmaceutical Development & Commercialization reported top-line results from the first of three Phase 3 trials for Sativex. The drug candidate is an investigational ...
Read Full Story »
Pills

Is a Generic Diovan for You?

Many investors have to worry about the so-called patent cliff in pharmaceutical companies. Generic launches are often priced into most analyst estimates, but these generic launches are always important to ...
Read Full Story »
downgrade sign

Analysts Predict Big Value Trap for Gilead Investors

AbbVie Inc. (NYSE: ABBV) and Express Scripts Holding Co. (NASDAQ: ESRX) entered into an exclusive distribution agreement following the U.S. Food and Drug Administration’s (FDA) approval of AbbVie’s hepatitis C ...
Read Full Story »
Pills

What the AbbVie and Express Script Deal Means for Gilead

AbbVie Inc. (NYSE: ABBV) received U.S. Food and Drug Administration (FDA) approval for its hepatitis C drug last Friday, and the drug will directly compete with treatments from Gilead Sciences Inc. ...
Read Full Story »
fda_logo

Is a Biosimilar (Generic) Top Cancer Drug for You?

There has been a movement to get generic pharmaceutical drugs to market with for years. The notion of "biosimilars" has grown as well. Effectively this is making biotech drugs into ...
Read Full Story »
Pfizer logo

What a Generic Celebrex Means for Pfizer and for Actavis

While this was generally a known event coming down the pipe, Celebrex now has a generic competitor in America. The drug company Actavis PLC (NYSE: ACT) announced on Wednesday that it ...
Read Full Story »